Kornimate/medical-research-clean huggingface dataset:
study of the effect of testosterone and estradiol on np responses to acute and chronic salt loading

Conditions: Hypertension

Summary: there is gender dimorphism in cardiovascular risk, with men at higher risk than women. however, the fundamental basis for the protective effect of female sex remains unclear. recent data implicate the natriuretic peptide (np) system as an important determinant of blood pressure. also, np levels are twice as high in women of reproductive age than in men, and gonadal steroids are important determinants of circulating nps. these are the marked, but poorly understood differences in the np status between men and women. the investigators hypothesize that gonadal steroids regulate np release, specifically that testosterone inhibits and estrogen activates the np axis, leading to differences in both resting np levels and dynamic responses of the np, raas, and kidneys to acute and chronic salt loading. understanding the basis for gender differences in np function should provide important insights regarding mechanisms underlying hypertension in men versus women.


Eligibility criteria:
inclusion criteria: * 18-40 years old * no history of hypertension * normal bmi * male: normal testosterone and free testosterone levels * female: regular menses, negative pregnancy test, no sex steroid therapy \>/=3 mos exclusion criteria: * on hypertensives, diuretics, or insulin * with diabetes mellitus * estimated creatinine clearance \<60 ml/min * prior cardiovascular, liver or renal disease * history of hormonally-responsive cancer * elevated liver function test (lfts) * atrial fibrillation * abnormal sodium or potassium levels * taking medications that directly impact the endocrine system (exogenous hormones, steroids, etc.) * taking medications that indirectly impact the endocrine system (ssris, opioids, finasteride, etc.) * with untreated hyper- or hypothyroidism * smoker * psychiatric history * women: not willing to abstain from getting pregnant during the course of the study, with abnormal menstrual cycle, or who have osteoporosis * men: with polycythemia

Keywords: natriuretic peptides
study to gather information how often venous thromboembolism occurs in prostate cancer patients in sweden and how this condition is treated with blood thinners

Conditions: Venous Thromboembolism (VTE)

Summary: patients with cancer are at a significantly increased risk of experiencing a venous thromboembolism (vte). vte is defined by a blood clot in the leg or lower extremity (deep vein thrombosis) or a blood clot in the lung (pulmonary embolism) and is a leading cause of condition of being diseased and death among cancer patients. the goal of the study is to gather information how often venous thromboembolism (vte) occurs in prostate cancer patients in sweden and how this condition is treated with blood thinners.


Eligibility criteria:
inclusion criteria: * initially all patients newly diagnosed with pca between 2007-2016 with at least one year before the end of follow up date (31 december 2017) will be included. from this population, a sub-population of pca patients with a first cancer-related vte event will be selected. exclusion criteria: * none
sensitivity of angiotensin ii type ii receptors in women following preeclampsia

Conditions: Preeclampsia Postpartum

Summary: women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. the reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. the purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women. the purpose of this study is to examine the microvascular differences in women who have had preeclampsia following activation of protective angiotensin receptors in the skin. this will help increase understanding of the mechanisms of angiotensin ii receptors in these women, and how activation of these receptors may restore microvascular function. in this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.


Eligibility criteria:
inclusion criteria: * women who had preeclampsia and women who did not have preeclampsia * 12 weeks to 5 years postpartum * 18-45 years old exclusion criteria: * history of hypertension or metabolic disease before pregnancy * history of gestational diabetes * skin diseases * current tobacco use * current antihypertensive medication * statin or other cholesterol-lowering medication * currently pregnant or planning to become pregnant * body mass index less than 18.5 kg/m2 * allergy to materials used during the experiment.(e.g. latex), * known allergy to study drugs
sustainability of vitamin d levels after repletion with ergocalciferol in chronic kidney disease stage 5d

Conditions: Vitamin D Deficiency; Renal Failure Chronic Requiring Hemodialysis

Summary: the prevalence of vitamin d deficiency increases as kidney function declines. as a result, many hemodialysis patients often have low levels of vitamin d. recent evidence has shown that vitamin d supplementation may improve many aspects of poor health such as heart disease and inflammatory markers. the objectives of this study are to determine how supplementing dialysis patients with ergocalciferol increases vitamin d levels, how long vitamin d levels can be maintained after a 6 month treatment course, and to examine the effect of ergocalciferol on biomarkers of inflammation and vascular health.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * activated vitamin d administration * on chronic hemodialysis for ≥ 6 months * use of a synthetic biocompatible dialysis membrane * 25-hydroxyvitamin d levels \< 30 ng/ml * corrected serum calcium \< 10.2 mg/dl * serum phosphate \< 7 mg/dl * iron replete (ferritin \> 200 ng/ml and transferrin saturation \> 20%) exclusion criteria: * current participation in any other investigational drug trial * vitamin d deficiency due to a heredity disorder * liver disease or failure * current or past treatment with ergocalciferol or cholecalciferol ≥ 2000 iu per day (within the past 6 months) * treatment with calcimimetics or bisphosphonates within the last 3 months * treatment with anti-epileptics or other medications that can effect vitamin d metabolism * malnutrition (serum albumin \< 2.5 mg/dl) * pregnancy, positive pregnancy test or breastfeeding * malignancy or other significant inflammatory disease * hiv/aids

Keywords: vitamin d ergocalciferol
phase 3 study randomized evaluating the efficacy of auriculotherapy in patients with musculoskeletal pain by aromatase inhibitors

Conditions: Musculoskeletal Pain; Breast Cancer

Summary: auriculotherapy is a complementary medicine, with few side effects, without contraindication, inexpensive and not very restrictive.its efficacy has been found in several tests especially for the treatment of intraoperative pain. it remains more controversial in other indications. evaluation of the value of auriculotherapy is often difficult because of the methodological limitations of the trials conducted. in the daily practice, the auriculotherapy is proposed to improve the articular pains of patients treated by aa. this phase iii study aims at validate this approach.


Eligibility criteria:
inclusion criteria: * patient over 18 years of age * patients with anti-aromatases in adjuvant treatment of breast cancer * menopausal women * treatment with aromatase inhibitors (anti-aromatase, aa) initiated for more than 3 months. in the case of a change in anti-aromatase, the last treatment must be started for more than 3 months. * musculoskeletal pain appearing or increased under aa: * overall pain score of qcd ≥3 (on a scale of 0 to 10) * pain on at least 2 sites * pain for at least 3 months * history of radiotherapy and / or adjuvant chemotherapy authorized * patients may have received tamoxifen * patient affiliated to a social security system * patient mastering the french language and able to complete the evaluation questionnaires * free and informed consent exclusion criteria: * patients who have already undergone treatment in auriculotherapy for the same indication * patient benefiting at the same time from a pncavt (acupuncture or homeopathy) for musculoskeletal pain * wearing hearing aids hindering the placement of semi-permanent needles (asp) * wearing of a valve prosthesis * patient under guardianship or unable to give informed consent * patient unable to undergo medical follow-up for geographical, social or psychopathological reasons

Keywords: auriculotherapy aromatase inhibitors adjuvant treatment
cytarabine (ara-c) in children with acute promyelocytic leukemia (apl)

Conditions: Leukemia

Summary: several groups, especially the pethema group (in their lpa96 and 99 trials), obtained low relapse rates in newly diagnosed acute promyelocytic leukemia (apl) patients by combining ll-transretinoic acid (atra) and anthracyclines without ara-c, suggesting that avoiding ara-c in the chemotherapy of apl reduced treatment toxicity without increasing relapses. while the relapse rate for the children with white blood cell(wbc) counts greater than 10×109/l at presentation were higher than those wbc counts less than 10×109/l (31% and 3.5%,respectively) in the lpa96 and 99 trials. a recent adult randomized trial show that avoiding ara-c leads to an increased risk of relapse in the apl patients with wbc counts less than 10×109/l. the role of the ara-c remains controversial. and there are very limited data reported on children with apl so far.

some studies suggest patients with high-risk disease should be treated with intensified doses of anthracycline, or intermediate/ high-dose ara-c or as2o3 as an early consolidation, so as to decrease the risk of relapse.however, a higher cumulative dose of anthracycline may lead to cardiac toxicity, especially for children. in addition, containing ara-c will led to more therapy-related toxicity. the benefit to add ara-c to the schedules is questionable and remains a matter of investigation in children.

Eligibility criteria:
inclusion criteria: * acute promyelocytic leukemia (apl) exclusion criteria: * \> 14

Keywords: ara-c as2o3 pediatric acute
the effect of calcitriol on progress and activity of lupus nephritis

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of this study is to determine whether calcitriol is effective in the treatment of lupus nephritis.

systemic lupus erythematosus (sle) is an autoimmune disease and renal involvement represent one of the most common manifestations of it . on the other hand, there is evidence that vitamin d and its analogs have known immunosuppressant properties and profound effects on glomerular mesangial cell proliferation. moreover much literature such as animal studies suggests it as a therapeutic intervention in autoimmune disease. the investigators plan to conduct a double blind randomized control clinical trial to study effects of calcitriol on progress and activity of lupus nephritis. fifty patients with clinically quiescent sle and biopsy-proven glomerulonephritis will be recruited. they will be treated with calcitriol for 1 year. proteinuria, renal function, lupus disease activity, serum inflammatory markers will be monitored.

Eligibility criteria:
inclusion criteria: * aged 18-65 years * baseline systemic lupus erythematosus disease activity index score \<= 4 * estimated glomerular filtration rate more than 15 ml/min/1.73m2 * proteinuria \> 1 g/day (or proteinuria \> 1 g/g-cr) in 2 consecutive samples within 12 weeks despite ace inhibitor at least 3 months * on maintenance dose of prednisolone \< 15 mg/day with or without other immunosuppressive medications * serum calcium level in normal range( 8.5-10.5 mg/dl) * history of biopsy-proven lupus nephritis clinical quiescent sle for at least 3 month * willingness to give written consent and comply with the study protocol exclusion criteria: * pregnancy, lactating or childbearing potential without effective method of birth control * severe gastrointestinal disorders that interfere with their ability to receive or absorb oral medication * history of malignancy, including leukemia and lymphoma within the past 2 years; systemic infection requiring therapy at study entry * any other severe coexisting disease such as, but not limited to, chronic liver disease, myocardial infarction, cerebrovascular accident, malignant hypertension * history of drug or alcohol abuse within past 2 years * vitamin d deficiency(25 hydroxy vitamin d less than 20ng/ml) * participation in any previous trial on vitamin d analogue * patients receiving treatment of vitamin d and/or its analogue for other medical reasons within the past 4 weeks * patients who are taking multivitamin supplement that contains vitamin d could be enrolled after 4 weeks of wash out period by changing to a preparation that has no vitamin d * on other investigational drugs within last 30 days * history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirement of the study * history of non-compliance; known history of sensitivity or allergy to vitamin d analogs

Keywords: lupus nephritis proteinuria sle calcitriol
pulmonary rehabilitation in non-chronic obstructive pulmonary disease patients.

Conditions: Pneumonia; Pulmonary Fibrosis; Tuberculosis; Bronchiectasis; Asthma

Summary: to determine the effect of pulmonary rehabilitation on pulmonary function in non-chronic obstructive pulmonary disease patients.to determine the effect of pulmonary rehabilitation on health related quality of life in non-chronic obstructive pulmonary disease patients.limited researches are available in non chronic obstructive pulmonary disease patients.

a review state that "interstitial lung disease presents clinical features of exertional desaturation and a nonproductive cough. patients with ild have significantly reduced exercise capacity as manifested by a reduced maximum work load achieved during exercise, as well as a reduced maximal oxygen uptake vo2max." in previous studies pulmonary rehabilitation is the use of exercise, education and behavioral interventions for diseases such as non-ild restrictive lung disease, asthma, lung cancer, bronchiectasis , and pulmonary hypertension, pre and post op thoracic surgery patients. quality of life (qol) as an individual's perception of contentment or satisfaction with life in areas he or she considers important, and we define health-related quality of life (hrql) as an individual's perception of the impact of health (in all its many facets) on his or her quality of life. a study on pulmonary rehabilitation outcomes between individuals with chronic obstructive lung disease (copd) and non-copd disease and its impact on gender.

Eligibility criteria:
inclusion criteria: * diagnosed cases of non-copd disease interstitial lung disease (pulmonary fibrosis), restrictive lung disease (tb, pneumonia), bronchiectasis, and asthma with fev1 below 50%, fvc\ 70% exclusion criteria: * clinically/vitally unstable or having uncontrolled dm/htn, current smokers or ex-smokers of less than 1 year.

Keywords: non-copd quality of life pulmonary function
evolution of the physical condition in treated cancer patients

Conditions: Non-small Cell Lung Cancer Metastatic; Breast Cancer Female; Colon Cancer

Summary: adaptated physical activity (apa) during treatment of cancer is one of the actual global health recommendation because of the benefits observed in several parameters evaluated in many clinical studies. a best knowledge of the physical and medical characteristics of patients, including type of cancer and type of treatment, is primordial to optimize the patient care and the effectiveness of apa programs. descriptive, explorative and prospective study of 3 different populations: one population with locally advanced or metastatic non-small cell lung cancer treated with multiple therapeutic lines. two different populations of early cancer patients and treated with a platinum-based regimen for colon cancer and a taxane-based chemotherapy for breast cancer.


Eligibility criteria:
inclusion criteria: * woman with breast cancer treated with adjuvant chemotherapy (taxane) or patient with colon cancer treated with adjuvant regimen (folfox) or patient with locally advanced or metastatic lung cancer * patient without contraindication to the study-specific assessments * eastern cooperative oncology group ≤ 2 * age ≥ 18 years old * life expectancy \> 6 months * able to speak, read and understand french * written informed consent obtained from the patient * registration in a national health care system exclusion criteria: * patient with psychiatric, neurologic or musculoskeletal disorders * pregnant or breastfeeding women * minor or protected adult
a study of the efficacy and safety of brensocatib in participants with chronic rhinosinusitis without nasal polyps (crssnp)

Conditions: Chronic Rhinosinusitis Without Nasal Polyps

Summary: the primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (qd) compared with placebo in improving clinical symptoms of crssnp.


Eligibility criteria:
inclusion criteria: * participants who have at least a 12-week history before screening visit of crssnp and confirmed by endoscopy at visit 1 (screening). * participants must have a ncs of ≥2 at visit 1 (screening visit) and visit 2 (baseline; average score in the week prior to randomization). * participants must have stss (nasal congestion \[nc\], anterior/posterior rhinorrhea, facial pain/pressure) ≥5 at visit 1 (screening) and at visit 2 (baseline; average score in the week prior to randomization). * participants who have at least 1 of the 3 following features: 1. previous sinonasal surgery for crs, including but not limited to fenestrated endoscopic sinus surgery and balloon sinuplasty. 2. received medical treatment with systemic corticosteroids (scs) to treat symptoms of crs as defined by any dose and duration within 1 year of screening visit or intolerance/contraindication to scs. 3. received a course of antibiotics to treat symptoms of crs within 1 year before the screening visit. * participants who have a blood eosinophil count ≤750 cells/microliter (μl) at visit 1 (screening). * participants who have bilateral inflammation of paranasal sinuses in the ct scan performed during screening and bilateral ethmoid and/or maxillary opacification before randomization as confirmed by the central reader. * participants who have a snot-22 score of ≥20 at visit 1 (screening) and visit 2 (baseline). * participants who have received a stable daily dose regimen of mfns for at least 4 weeks before visit 2 (baseline). exclusion criteria: * diagnosis of unilateral or bilateral chronic rhinosinusitis with nasal polyps (crswnp). * clinical diagnosis of cystic fibrosis (cf) or primary ciliary dyskinesia. * scheduled sinus surgery at any time during the study. * participants who have had nasal surgery within 4 weeks before visit 1 (screening) and during the screening period. * significant oral maxillofacial structural abnormalities or severe septal deviation. * participants with radiological suspicion or confirmed invasive fungal rhinosinusitis, odontogenic sinusitis, osteomas, or nasal tumors. * participants with acute change in symptoms consistent with acute rhinosinusitis. * participants with seasonal allergic rhinitis whose symptoms coincide with the treatment period of the study. * participants with moderate to severe atopic dermatitis requiring treatment with high potency topical steroids or topical calcineurin inhibitors or biologics. * clinical diagnosis of papillon-lefèvre syndrome. note: other inclusion/exclusion criteria may apply.

Keywords: crssnp
ultrasound for assessment of intra-abdominal blood loss after gynecological surgery

Conditions: Post-Operative Hematoma at Operative Site (Diagnosis); Post-Operative Hemorrhage

Summary: this is a prospective cohort study designed to assess intra-abdominal blood volume and hemodynamic status by measuring the diameter of the inferior vena cava (ivc) using 3d and doppler ultrasound within 24 hours after gynecological surgery. the study will examine the association between these ultrasound findings and postoperative outcomes, including hemoglobin drop, need for blood transfusion, pain, infection, and length of hospitalization. approximately 250 women undergoing laparotomy, laparoscopy, or vaginal surgery at holy family hospital will be enrolled. the study also aimed to define postoperative normograms for fluid volume and ivc parameters and to evaluate whether ultrasound-guided decision-making could improve postoperative care and reduce unnecessary interventions.

postoperative intra-abdominal bleeding is a significant contributor to morbidity and, in some cases, mortality following gynecological surgery. timely recognition of intra-abdominal blood loss is essential for appropriate clinical intervention. in cases where bleeding is into the abdominal cavity, diagnosis is more difficult and may be delayed. ultrasound is a non-invasive, rapid, and widely available tool for assessing free intra-abdominal and pelvic fluid. modern machines allow for 3d volumetric assessment of fluid collections, as well as doppler-based measurements of the inferior vena cava (ivc) diameter and its collapsibility index-both of which are known to correlate with intravascular volume status and blood loss. currently, there are limited data establishing normal ranges of intra-abdominal fluid or ivc diameter postoperatively, and little is known about the magnitude of these measurements and clinical outcomes after gynecologic procedures. this prospective cohort study aims to quantify intra-abdominal fluid and determine ivc diameter and its collapsibility index using advanced ultrasound imaging within 24 hours after surgery. patients undergoing open, laparoscopic, or vaginal gynecological procedures will be included. the study will explore correlations between ultrasound findings and clinical outcomes such as hemoglobin drop, need for blood transfusion, infection, pain, and length of hospital stay. additionally, we aim to develop reference normograms for postoperative normal ranges of intraabdominal fluid volume and ivc diameter.

Eligibility criteria:
inclusion criteria: * women aged 18 years and older * undergoing gynecological surgery including laparotomy, laparoscopy, and vaginal pelvic surgery * able to provide informed consent exclusion criteria: * undergoing minor procedures (e.g., dilation and curettage, hysteroscopy, or cervical conization) * known preoperative coagulation disorders * postoperative admission to the intensive care unit (icu) * clinical indication requiring ultrasound as part of standard postoperative care
a single-center pilot study to assess macular function

Conditions: Macular Degeneration

Summary: this study seeks to evaluate a novel endpoint for future dry amd clinical trials.


Eligibility criteria:
inclusion criteria: * subjects in good health aged 20-29 or 60-90 years (normal cohorts) * subjects with early non-exudative age-related macular degeneration (amd cohort) exclusion criteria: * enrollment in a investigational drug or device study and have used an investigational drug or device within 7 days of enrollment into this study

Keywords: non-exudative age-related macular degeneration